Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer

Abstract

Spermatogenesis-associated 19 (SPATA19) is a cancer/testis antigen overexpressed in various cancers. However, its protein expression profile in malignant or non-malignant tissues remains unknown. Thus, in this study, we investigated SPATA19 protein expression patterns in a panel of non-malignant human samples and primary prostate cancer (PCa) with or without benign prostatic hyperplasia (BPH) tissues. SPATA19 was absent in all non-malignant tissues investigated (n=14) except testis and prostate tissues. In terms of malignancies, all PCa cases were positive for SPATA19 exhibiting frequency between 20 and 100% (median 85%) with 63 (52.5%) and 57 (47.5%) cases demonstrating weak/moderate and strong intensities, respectively. Thirty-nine PCa cases (32.5%) contained BPH, and all BPH glands were SPATA19 positive (frequency between 20 and 100%; median 90%) with 13 (33.3%) demonstrating strong SPATA19 expression. Higher SPATA19 expression (higher frequency, intensity, or H-score) was not associated with overall survival or disease-specific survival (DFS) in all PCa cases. However, biochemical recurrence (BR) was associated with worse DFS (p = 0.005) in this cohort of 120 patients, and cases with strong SPATA19 intensity were associated with BR (p = 0.020). In conclusion, we showed that SPATA19 protein was frequently expressed in both BPH and PCa glands, and this warrants future investigations on its pathogenic roles in the disease.

Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

“…Pathology of the Spanish and Norwegian cohorts was centrally reviewed by an experienced uropathologist (José I. López and Ljiljana Vlatkovic, respectively), who were blinded with respect to patient outcome, using the 2005 ISUP consensus and the ADASP practice guidelines 33 . Both prostate cancer cohorts have been previously described 34,35 . Ethical approvals, including informed consent from all included patients, have been obtained for both cohorts (Clinical research ethical committee [CEIC] number E16/51 from Spain and Regional Committees for Medical Research Ethics [REK] number S‐07443a from Norway).…”

“…33 Both prostate cancer cohorts have been previously described. 34,35 Ethical approvals, including informed consent from all included patients, have been obtained for both cohorts (Clinical research ethical committee [CEIC] number E16/51 from Spain and Regional Committees for Medical…”

Sperm mitochondria dysfunction in response to testicular cancer

“…59 It has been shown that these CTAs are involved in a variety of cancers such as breast, prostate, melanoma and lung neoplasia. 59,[67][68][69] So far, the information is missing on the abovementioned CTAs in testicular cancer. Their aberrant expression needs to be studied, particularly in mitochondria-related CTAs, with relevance to testicular tumours and sperm anomalies.…”

“…Specifically, CTAs such as spermatogenesis‐associated‐protein 19 (SPATA19), glycerol‐3‐phosphate acyltransferase 2 (GPAT2), foetal and adult testis expressed 1 (FATE1), cytochrome C oxidase subunit 6B2 (COX6B2), and KIAA0100 are related to mitochondrial function 59 . It has been shown that these CTAs are involved in a variety of cancers such as breast, prostate, melanoma and lung neoplasia 59,67–69 . So far, the information is missing on the abovementioned CTAs in testicular cancer.…”

LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer

“…The proteasome subunit alpha type may be significantly associated with the protein metabolism in the body, and its expression is associated with cancer [30,31]. The spermatogenesis-associated protein is a spermatogenesis-related protein that is mainly found in mammalian tissues and is significantly elevated in prostate cancer tissues [32], testicular cancer tissues [32,33], and breast cancer tissues [34]. The expression of spermatogenesis-associated 6 (SPATA6) is significantly elevated in testicular cancer, and inhibition of SPATA6 Prostatespecific antigen expression in lung adenocarcinoma groups was significantly lower in the metastatic groups than in the non-metastasis groups.…”